OncoMatch/Clinical Trials/NCT07255963
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
Is NCT07255963 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pirtobrutinib and Lisaftoclax for dlbcl - diffuse large b cell lymphoma.
Treatment: Pirtobrutinib · Lisaftoclax · Rituximab — This study aims to evaluate the efficacy of combining pirtobrutinib, lisaftoclax, and rituximab (PVR) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy and to explore a more effective treatment strategy for this patient population.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: systemic therapy — DLBCL
Have received at least one prior line of systemic therapy for DLBCL.
Cannot have received: pirtobrutinib (pirtobrutinib)
Prior treatment failure or resistance to pirtobrutinib
Cannot have received: BCL2 inhibitor
Prior treatment failure or resistance to BCL2 inhibitors
Cannot have received: chemotherapy
Exception: within the specified washout period
Chemotherapy, radiotherapy, immunotherapy, or antibody-based anticancer therapy within the specified washout period.
Cannot have received: radiotherapy
Exception: within the specified washout period
Chemotherapy, radiotherapy, immunotherapy, or antibody-based anticancer therapy within the specified washout period.
Cannot have received: immunotherapy
Exception: within the specified washout period
Chemotherapy, radiotherapy, immunotherapy, or antibody-based anticancer therapy within the specified washout period.
Cannot have received: antibody-based anticancer therapy
Exception: within the specified washout period
Chemotherapy, radiotherapy, immunotherapy, or antibody-based anticancer therapy within the specified washout period.
Cannot have received: traditional Chinese herbal medicine with antitumor indications
Traditional Chinese herbal medicine with antitumor indications.
Cannot have received: small-molecule targeted therapy
Exception: within 2 weeks before study treatment initiation
Small-molecule targeted therapy within 2 weeks before study treatment initiation.
Cannot have received: antibody-drug conjugate
Exception: within 10 weeks before study treatment initiation
ADCs or cytotoxic therapy within 10 weeks before study treatment initiation.
Cannot have received: cytotoxic chemotherapy
Exception: within 10 weeks before study treatment initiation
ADCs or cytotoxic therapy within 10 weeks before study treatment initiation.
Cannot have received: allogeneic hematopoietic stem cell transplantation
Prior allogeneic hematopoietic stem cell transplantation (HSCT) or planned allogeneic HSCT.
Lab requirements
Blood counts
anc≥1.5 × 10⁹/l, platelets ≥80 × 10⁹/l, hemoglobin ≥80 g/l
Kidney function
serum creatinine ≤1.5 × uln or estimated creatinine clearance (crcl) ≥60 ml/min
Liver function
total bilirubin ≤1.5 × uln (≤3.0 × uln if liver metastases present); ast/sgot and alt/sgpt ≤2.5 × uln (≤5.0 × uln if liver metastases present)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify